MedTrace Logo

CLAD Phenotype Specific Risk Factors and Mechanisms

NCT02631720 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 884

Last updated 2019-12-17

No results posted yet for this study

Summary

While many patients experience benefits from transplant, complications such as infections and lung rejection may affect long term survival and quality of life. In this study doctors are looking at a complication called Chronic Lung Allograft Dysfunction (CLAD). CLAD is thought to be chronic rejection of the lung by the immune system and is the leading cause of death after lung transplantation.

The purpose of this study is to help doctors determine:

* why some people get CLAD and others do not
* how patients who get CLAD do after CLAD is diagnosed
* how CLAD may affect quality of life

Conditions

  • Lung Transplant
  • Post Lung Transplantation

Interventions

PROCEDURE

Blood Draw

PROCEDURE

Bronchoscopy

Sponsors & Collaborators

  • Clinical Trials in Organ Transplantation

    collaborator NETWORK

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Scott M Palmer, MD, MHS · Duke University

  • John Belperio, MD · University of California, Los Angeles

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-22
Primary Completion
2019-11-30
Completion
2019-11-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631720 on ClinicalTrials.gov